Results 11 to 20 of about 21,277,776 (188)

sPD-1/sPD-L1 proteins in non-small cell lung cancer and esophageal squamous cell carcinoma

Бюллетень сибирской медицины, 2022
Background. Implementation of immunotherapy in clinical oncological practice has significantly improved the results of cancer treatment. It resulted in the need for seeking new markers to assess the effectiveness of therapy and the disease prognosis.Aim.
I. S. Stilidi, O. V. Kovaleva, A. N. Gratchev, E. M. Tchevkina, P. A. Podlesnaya, P. V. Tsarapaev, E. A. Suleymanov, N. E. Kushlinskii   +7 more
doaj   +4 more sources

Expression and its clinical significance of sPD-1 and sPD-L1 in patients with primary nephrotic syndrome

Linchuang shenzangbing zazhi, 2020
Objective To investigate expression and its clinical significance of soluble programmed death protein 1(sPD-1) and soluble programmed death ligand 1(sPD-L1) in patients with primary nephrotic syndrome(PNS).Methods A total of 87 PNS patients admitted to ...
LV Zhi-an, WANG Juan-ni, YANG Yan-yan
doaj   +2 more sources

Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer. [PDF]

Diagnostics (Basel), 2022
It is crucial to find new diagnostic and prognostic biomarkers. A total of 80 patients were enrolled in the study. The study group consisted of 37 patients with epithelial ovarian cancer, and the control group consisted of 43 patients with benign ovarian cystic lesions.
Świderska J, Kozłowski M, Nowak K, Rychlicka M, Branecka-Woźniak D, Kwiatkowski S, Pius-Sadowska E, Machaliński B, Cymbaluk-Płoska A.   +8 more
europepmc   +5 more sources

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer

OncoImmunology, 2017
Up to now, the efficacy of programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) blockade in pancreatic cancer (PC) remains uncertain. Serum levels of soluble PD-1 and PD-L1 (sPD-1/sPD-L1) have been reported to be independent prognostic ...
Stephan Kruger, Marie-Louise Legenstein, Verena Rösgen, Michael Haas, Dominik Paul Modest, Christoph Benedikt Westphalen, Steffen Ormanns, Thomas Kirchner, Volker Heinemann, Stefan Holdenrieder, Stefan Boeck   +10 more
doaj   +2 more sources

Study on the efficacy of IFN-γ- and sPD-1-overexpressing BMSCs in enhancing immune effects for the treatment of lung adenocarcinoma. [PDF]

Front Immunol
BackgroundSoluble programmed cell death receptor-1 (sPD-1) blocks the PD-1/PD-L1 pathway, reverses tumor immune suppression, and inhibits tumor growth. However, clinical applications are limited by its poor tissue distribution and rapid dispersion. Bone marrow-derived mesenchymal stem cells (BMSCs) are favorable carriers for tumor immunotherapy due to ...
Xie Y, Lv Z, Wang Y, Ma J, Wei X, Zheng G, Wu J.   +6 more
europepmc   +4 more sources

The Prognostic Value of Serum Soluble Programmed Death 1 (sPD‐1) and Programmed Death Ligand 1 (sPD‐L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta‐Analysis About Cohort Studies [PDF]

Health Science Reports
Background and Aims There are still no useful biomarkers for the prognosis of esophageal squamous cell carcinoma (ESCC). In the prognosis of some kinds of cancer, soluble programmed death 1 (sPD‐1) and programmed death ligand 1 (sPD‐L1) have demonstrated
Qiyao Yu, Jie Li, Wenjie Mao, Zheng Li, Xuan Li, Bin Li   +5 more
doaj   +2 more sources

Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma. [PDF]

Clinics (Sao Paulo)
This study aimed to explore the effects of Apatinib combined with Temozolomide (TMZ) on the levels of Soluble PD-1 (sPD-1) and Soluble Programmed Death-1 Ligand (sPD-L1) in patients with drug-resistant recurrent Glioblastoma (GB).A total of 69 patients with recurrent GB from September 2020 to March 2022 were recruited and assigned to the control group (
Kuang RZ, Wang J, Wang YC, Tang XP.
europepmc   +4 more sources

Prognostic significance of sPD-1/sPD-L1 in renal cancer depending on the phenotype of tumor and stromal cells

Cancer Urology, 2022
Background. The search for new prognostic markers of renal cell carcinoma is an urgent problem of oncourology. Modern studies demonstrate the need for a comprehensive assessment of the clinical and prognostic significance of many markers.Aim is a comprehensive analysis of the prognostic significance of soluble forms of PD-1 and PD-L1 (sPD-1 and sPD-L1)
O. V. Kovaleva, A. N. Gratchev, E. I. Makarova, S. D. Bezhanova, I. S. Stilidi, V. B. Matveev, N. E. Kushlinskii   +6 more
openaire   +3 more sources

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer

Frontiers in Oncology, 2019
Introduction: Response to platinum-based therapy is a major prognostic factor in epithelial ovarian cancer (EOC) and reliable prognostic biomarkers are urgently needed to identify patients at high risk.
Paul Buderath, Esther Schwich, Christina Jensen   +2 more
exaly   +3 more sources

Soluble PD-1 (sPD-1) is expressed in human macrophages

Cellular Immunology, 2021
The PD-1/PD-L1 axis plays a crucial role in regulating the anti-tumour immune response. A soluble PD-1 protein (sPD-1) has previously been observed, which could block the binding of PD-L1 to PD-1. Tumour associated macrophages are abundant in tumours, and evidence suggest they express PD-1. However, whether they also express sPD-1 remains unclear.
Antonsen, Kristian W; id_orcid 0000-0002-1867-2222, Hviid, Claus V B, Hagensen, Mette K, Sørensen, Boe S; id_orcid 0000-0002-9472-8099, Møller, Holger J   +4 more
openaire   +3 more sources